These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33838348)

  • 1. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.
    Narula N; Wong ECL; Dulai PS; Sengupta NK; Marshall JK; Colombel JF; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1579-1587.e2. PubMed ID: 33838348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn's Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Shehab M; Alrashed F; Heron V; Restellini S; Bessissow T
    Inflamm Bowel Dis; 2023 Mar; 29(3):367-375. PubMed ID: 35604382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
    Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
    Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
    J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis.
    Narula N; Wong ECL; Marshall JK; Colombel JF; Dulai PS; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1588-1597.e3. PubMed ID: 34329776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study.
    Wong ECL; Merat S; Monaco C; Dulai PS; Jairath V; Marshall JK; Reinisch W; Narula N
    Dig Dis Sci; 2023 Jun; 68(6):2635-2646. PubMed ID: 37119375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
    Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
    Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
    Kucharzik T; Wilkens R; D'Agostino MA; Maconi G; Le Bars M; Lahaye M; Bravatà I; Nazar M; Ni L; Ercole E; Allocca M; Machková N; de Voogd FAE; Palmela C; Vaughan R; Maaser C;
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):153-163.e12. PubMed ID: 35842121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
    Singh S; Fumery M; Sandborn WJ; Murad MH
    Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
    Narula N; Wong ECL; Dulai PS; Marshall JK; Colombel JF; Reinisch W
    J Crohns Colitis; 2021 Oct; 15(10):1649-1657. PubMed ID: 33693522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy with adalimumab, ustekinumab and methotrexate for induction of remission in moderate to severe ileocolonic Crohn's disease with upper gastrointestinal involvement in a biologic-experienced individual.
    Yu N; Sarwal D; Ash R; Aslinia FM
    BMJ Case Rep; 2021 Oct; 14(10):. PubMed ID: 34645625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Ren H; Kang J; Wang J; Su J; Zou L; Yin A; Li J; Zhou Q; Wang W; Tang Z; Zhang J; Lu Y; Yang Y; Qiu C; Ding Y; Dong W; An P
    Inflamm Bowel Dis; 2024 Aug; 30(8):1295-1302. PubMed ID: 37619248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.